ArticleThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2019
Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide.
Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diffusing capacity in chronic obstructive pulmonary disease assessment: A meta-analysis.Chronic respiratory diseasePooled it
- Navigating the Complexity of PH-ILD: From Molecular Mechanisms to Integrated Clinical Evaluation.International journal of molecular sciences · 2026Review
- Diffusing Capacity of the Lung for Carbon Monoxide and the Risk of All-Cause Mortality in Patients With Pulmonary Hypertension Caused by Fibrosing Mediastinitis: A Multicenter Cohort Study.Pulmonary circulation · 2026Article
- Successful Single Lung Transplantation in Severe Group III Pulmonary Hypertension.Annals of thoracic surgery short reports · 2026Article
- Clinical, Functional, and Comorbid Characteristics of COPD Patients with Impaired Diffusing Capacity: A Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Article
- Pulmonary vasodilator therapy is associated with improved survival in COPD-PH with pulmonary vascular predominance.BMC pulmonary medicine · 2026Article
- Patient-Specific Lumped-Parameter Model for Quantifying Vessel-Specific Remodeling and Predicting Right Ventricular Function in Pulmonary Hypertension.Comprehensive Physiology · 2026Article
- Nomograms to predict severe PH and survival in COPD patients using non-invasive parameters.Frontiers in medicine · 2026Article
- Pulmonary hypertension associated with nonparenchymal restrictive lung diseases.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Phenotypic Analysis of Pulmonary Hypertension Associated With Low Diffusion Capacity and Preserved Lung Function.Pulmonary circulation · 2025Article
- Significance of Pulmonary Vascular Dysfunction in Chronic Obstructive Pulmonary Disease.Pulmonary circulation · 2025Review
- Machine Learning Analysis of Electronic Health Records Identifies Interstitial Lung Disease and Predicts Mortality in Patients with Systemic Sclerosis.medRxiv : the preprint server for health sciences · 2025Article
- Iron Replacement Attenuates Hypoxic Pulmonary Hypertension by Remodeling Energy Metabolism via Regulating the HIF2α/Mitochondrial Complex I, III/ROS Axis.Biomolecules · 2025Article
- Promotor Hypomethylation Mediated Upregulation of VCAN Targets Twist1 to Promote EndMT in Hypoxia-Induced Pulmonary Hypertension.Journal of the American Heart Association · 2024Article
- COPD associated pulmonary hypertension: A post hoc analysis of the PERFECT study.Pulmonary circulation · 2024Article
- Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH-CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative-group 3 pulmonary hypertension.Pulmonary circulation · 2024Review
- Pulmonary hypertension associated with lung diseases.The European respiratory journal · 2024Review
- Catheter-based examination for pulmonary microcirculatory function in patients with pulmonary hypertension.PloS one · 2024Article
- Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension.Pulmonary circulation · 2024Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
backgroundPatients with pulmonary hypertension (PH) due to chronic lung disease (Group 3 PH) have poor long-term outcomes. However, predictors of survival in Group 3 PH are not well described.
methodsWe performed a cohort study of Group 3 PH patients (n = 143; mean age 65 ± 12 years, 52% female) evaluated at the University of Minnesota. The Kaplan-Meier method and Cox regression analysis were used to assess survival and predictors of mortality, respectively. The clinical characteristics and survival were compared in patients categorized by PH severity based on the World Health Organization (WHO) classification and lung disease etiology.
resultsAfter a median follow-up of 1.4 years, there were 69 (48%) deaths. The 1-, 3-, and 5-year survival rates were 79%, 48%, and 31%. Age, coronary artery disease, atrial fibrillation, Charlson comorbidity index, serum N-terminal pro‒brain natriuretic peptide (NT-proBNP), creatinine, diffusion capacity of carbon monoxide (DLCO), total lung capacity, left ventricular ejection fraction, right atrial and right ventricular enlargement on echocardiography, cardiac index, and pulmonary vascular resistance (PVR) were univariate predictors of survival. On multivariable analysis, DLCO was the only predictor of mortality (adjusted hazard ratio [HR] for every 10% decrease in predicted value: 1.31 [95% confidence interval 1.12 to 1.47]; p = 0.003). The 1-/5-year survival by tertiles of DLCO was 84%/56%, 82%/44%, and 63%/14% (p = 0.01), respectively. On receiver-operating characteristic curve analysis, DLCO <32% of predicted had the highest sensitivity and specificity for predicting survival. The 1- and 5-year survival in patients with a DLCO ≥32% predicted was 84% and 60% vs 68% and 13% in patients with a DLCO <32% predicted (adjusted HR: 2.5 [95% confidence interval 1.3 to 5.0]; p = 0.007). Lung volumes and DLCO were not related, but higher PVR was strongly associated with reduced DLCO. There was increased mortality in interstitial lung disease‒PH as compared with chronic obstructive pulmonary disease‒PH, but PH severity based on the WHO classification did not alter survival.
conclusionsLow DLCO is a predictor of mortality and should be used to risk-stratify Group 3 PH patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.